ライフサイエンスコーパス: cognitive therapy

1 cognitive therapy (thus, 71% did not accept cognitive therapy).

2 f a mood disorder were more likely to accept cognitive therapy.

3 more rapid remission than augmentation with cognitive therapy.

4 ide if necessary; others received individual cognitive therapy.

5 and comparable overall outcomes to standard cognitive therapy.

6 ssion rates were 46% for medication, 40% for cognitive therapy.

7 iversity, where medications were superior to cognitive therapy.

8 s to treat pharmacologically, but respond to cognitive therapies.

9 .61 to -10.23]; 11 trials and 287 patients), cognitive therapy (-13.36 [-18.40 to -8.21]; six trials

10 herapy for PTSD, 3 months of standard weekly cognitive therapy, 3 months of weekly emotion-focused su

11 eks, response rates in medications (50%) and cognitive therapy (43%) groups were both superior to the

12 e, < or =9) were significantly greater after cognitive therapy (58%) and phenelzine (58%) than after

13 Intensive cognitive therapy achieved faster symptom reduction and

14 ly more side effects than those who received cognitive therapy alone.

15 Phenelzine and cognitive therapy also reduced symptoms significantly mo

16 changes in the brain have been observed with cognitive therapy and certain forms of meditation and le

17 reating pain and depression in FMS by adding cognitive therapy and coping skills components to a comp

18 f the conceptual and practical components of cognitive therapy and highlights some of the empirical e

19 of the depression-specific psychotherapies, cognitive therapy and interpersonal therapy, is reviewed

20 The authors compared the effectiveness of cognitive therapy and pharmacotherapy as second-step str

21 mization strata that permitted comparison of cognitive therapy and pharmacotherapy.

22 The scores between cognitive therapy and phenelzine did not differ signific

23 versus any augmentation strategy (including cognitive therapy), and a medication switch strategy onl

24 d all treatment strategies, 3% accepted only cognitive therapy, and 26% accepted cognitive therapy (t

25 step treatments: cognitive therapy versus no cognitive therapy, any switch strategy versus any augmen

26 Mindfulness-based cognitive therapy appears efficacious as a treatment for

27 These findings support the efficacy of meta-cognitive therapy as a viable psychosocial intervention.

28 Patients receiving cognitive therapy as compared with those receiving stand

29 augmentation was more rapidly effective than cognitive therapy augmentation of citalopram, whereas sw

30 Cognitive therapy can be as effective as medications for

31 Cognitive therapy can be successful in promoting clinica

32 Cognitive therapy combined with ADM treatment enhances t

33 psychotherapy for atypical depression or of cognitive therapy compared with a monoamine oxidase inhi

34 low-up evaluation, patients who had received cognitive therapy continued to improve, while those in t

35 Cognitive therapy (CT) may reduce depressive relapse and

36 A pilot study of cognitive therapy (CT) specifically designed to prevent

37 risk of relapse/recurrence after acute phase cognitive therapy (CT), a continuation phase model of th

38 Cognitive therapy (CT), often labeled as the generic ter

39 in controlled trials, 40% to 60% respond to cognitive therapy (CT).

40 little more than a week was as effective as cognitive therapy delivered over 3 months.

41 to second-step treatment, those who received cognitive therapy (either alone or in combination with c

42 ivational interviewing, relaxation training, cognitive therapy, exposure, problem-solving skills trai

43 8 (50%) of 197 participants were assigned to cognitive therapy for command hallucinations + treatment

44 ther people were assigned in a 1: 1 ratio to cognitive therapy for command hallucinations + treatment

45 e voices compared with 22 (28%) of 79 in the cognitive therapy for command hallucinations + treatment

46 and efficacy of a 7-day intensive version of cognitive therapy for PTSD and to investigate whether co

47 Cognitive therapy for PTSD delivered intensively over li

48 Intensive cognitive therapy for PTSD is a feasible and promising a

49 ) were randomly allocated to 7-day intensive cognitive therapy for PTSD, 3 months of standard weekly

50 rious adverse events: two in patients in the cognitive therapy group (one attempted overdose and one

51 ly greater proportion of members of the meta-cognitive therapy group demonstrated improvement compare

52 ed the efficacy of a 12-week manualized meta-cognitive therapy group intervention designed to enhance

53 total scores were consistently lower in the cognitive therapy group than in the treatment as usual g

54 cognitive therapy group, 77% of the standard cognitive therapy group, 43% of the supportive therapy g

55 atment/wait assessment, 73% of the intensive cognitive therapy group, 77% of the standard cognitive t

56 Cognitive therapy has an enduring effect that extends be

57 therapy for PTSD and to investigate whether cognitive therapy has specific treatment effects by comp

58 Cognitive therapy is a system of psychotherapy with a po

59 Cognitive therapy is an effective intervention for recen

60 a critical window during which prophylactic cognitive therapy may benefit people at risk of schizoph

61 Cognitive therapy may offer an effective alternative to

62 or insomnia, especially stimulus control and cognitive therapy, may be a helpful adjunct to treatment

63 Mindfulness-based cognitive therapy (MBCT) has been shown to reduce risk o

64 ought to determine whether mindfulness-based cognitive therapy (MBCT) reduces distress in men with ad

65 g (n = 85) were randomly assigned to receive cognitive therapy (n = 28), a self-help booklet based on

66 e paroxetine (n = 120), placebo (n = 60), or cognitive therapy (n = 60).

67 ion [N=56] or buspirone [N=61]) or switch to cognitive therapy (N=36) or another antidepressant (N=86

68 ts to either augmentation of citalopram with cognitive therapy (N=65) or medication (N=117; either su

69 the cognitive theory of psychopathology and cognitive therapy of specific psychiatric disorders was

70 Cognitive therapy (often labeled generically as cognitiv

71 One treatment also adds cognitive therapy, one adds supportive-expressive psycho

72 who consented to random assignment to either cognitive therapy or alternative pharmacologic strategie

73 ized, controlled trial comparing acute-phase cognitive therapy or clinical management plus either phe

74 otherwise randomly assigned to receive meta-cognitive therapy or supportive psychotherapy in a group

75 ng education, certain medications, exercise, cognitive therapy, or all 4 should be recommended.

76 At follow-up, fewer cognitive therapy patients (3 [11%]) had PTSD compared w

77 psychiatric severity and the superiority of cognitive therapy plus GDC compared with supportive-expr

78 counseling plus group drug counseling (GDC), cognitive therapy plus GDC, supportive-expressive therap

79 Cognitive therapy plus standard treatment vs standard tr

80 als were randomly assigned to receive either cognitive therapy plus treatment as usual (n=37), or tre

81 muted block sizes of four or six, to receive cognitive therapy plus treatment as usual, or treatment

82 = 49) or usual care plus a 15-session group cognitive therapy prevention program (n = 45).

83 = 49) or usual care plus a 15-session group cognitive therapy prevention program (n = 45).

84 A brief, group cognitive therapy prevention program can reduce the risk

85 Cognitive therapy produced greater personality change th

86 d at the level of a nonsignificant trend for cognitive therapy relative to placebo.

87 roxetine responders (P = .003) but not among cognitive therapy responders (P = .86).

88 Cognitive therapy responders at higher risk for relapse

89 ssion effectively, but there is less data on cognitive therapy's effects in this population.

90 The cognitive therapy scale showed no difference for nonspec

91 Patients treated with cognitive therapy showed a clinically significant mean i

92 Cognitive therapy significantly reduced psychiatric symp

93 -i incorporated at least 3 of the following: cognitive therapy, stimulus control, sleep restriction,

94 there is only 1 placebo-controlled trial of cognitive therapy, this trial fills a gap in the literat

95 ted only cognitive therapy, and 26% accepted cognitive therapy (thus, 71% did not accept cognitive th

96 We therefore tested our new cognitive therapy to challenge the perceived power of vo

97 The findings have implications for using cognitive therapy to reduce defeatist attitudes that may

98 Meta-cognitive therapy uses cognitive-behavioral principles a

99 ity of the following second-step treatments: cognitive therapy versus no cognitive therapy, any switc

100 entation of citalopram, whereas switching to cognitive therapy was better tolerated than switching to

101 Cognitive therapy was compared with medication augmentat

102 We aimed to establish whether cognitive therapy was effective in reducing psychiatric

103 Cognitive therapy was more effective in reducing symptom

104 Acceptance of cognitive therapy was primarily associated with sociodem

105 and general anxiety, intensive and standard cognitive therapy were superior to supportive therapy.

106 s by comparing intensive and standard weekly cognitive therapy with an equally credible alternative t

107 Meta-cognitive therapy yielded significantly greater improvem